Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Lantern Pharma Inc
(NQ:
LTRN
)
4.230
-0.060 (-1.40%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lantern Pharma Inc
< Previous
1
2
3
4
5
6
Next >
LTRN Stock Earnings: Lantern Pharma Beats EPS for Q2 2024
August 08, 2024
LTRN stock results show that Lantern Pharma beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates
August 08, 2024
From
Lantern Pharma Inc.
Via
Business Wire
Lantern Pharma Highlights Promising Preclinical Results of LP-184’s Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024
August 07, 2024
From
Lantern Pharma
Via
Business Wire
Recap: Lantern Pharma Q4 Earnings
March 18, 2024
Via
Benzinga
Lantern Pharma Earnings Preview
March 15, 2024
Via
Benzinga
Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort
August 05, 2024
From
Lantern Pharma
Via
Business Wire
Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET
August 01, 2024
From
Lantern Pharma Inc.
Via
Business Wire
Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184
July 10, 2024
From
Lantern Pharma
Via
Business Wire
Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284
June 12, 2024
From
Lantern Pharma Inc.
Via
Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
May 13, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
May 10, 2024
Via
Benzinga
LTRN Stock Earnings: Lantern Pharma Misses EPS for Q1 2024
May 09, 2024
LTRN stock results show that Lantern Pharma missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights
May 09, 2024
From
Lantern Pharma Inc.
Via
Business Wire
Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism
May 06, 2024
From
Lantern Pharma Inc.
Via
Business Wire
Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET
May 02, 2024
From
Lantern Pharma Inc.
Via
Business Wire
3 Machine Learning Stocks with the Potential to Make You an Overnight Millionaire
May 01, 2024
Keep an eye on machine learning stocks. With big demand, we could be looking at a half-trillion-dollar market by 2030.
Via
InvestorPlace
Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development
April 24, 2024
From
Lantern Pharma Inc.
Via
Business Wire
Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan
April 22, 2024
From
Lantern Pharma Inc.
Via
Business Wire
Why Wang & Lee Group Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
April 19, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
April 11, 2024
Via
Benzinga
Software Segment of Global A.I. Healthcare Billion Dollar Market Expected to Have Fastest Growth
April 10, 2024
EQNX::TICKER_START (OTCQB:TREIF),(CSE:TRUE),(NYSE:MDT),(NASDAQ:NVDA),(NASDAQ:LTRN),(OTCQX:HWAIF),(TSX:AIDX) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Product Safety
AI Sector Stalling: Only 4 Of 7 Categories Went Up In March
March 31, 2024
No AI category went down in February, but 3 did in March - confirming my comment last week that
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Six Of Seven AI Stock Categories Increased This Week
March 23, 2024
All but one of the 7 artificial intelligence stock categories that I analyze weekly increased in value this week. But two categories are still down MTD, suggesting that the surge in the artificial...
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028
March 20, 2024
EQNX::TICKER_START (OTCQB:TREIF),(CSE:TRUE),(OTCQX:HWAIF),(OTCQB:VRSSF),(NYSE:PATH),(NASDAQ:LTRN) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
12 Health Care Stocks Moving In Tuesday's Intraday Session
March 19, 2024
Via
Benzinga
LTRN Stock Earnings: Lantern Pharma Beats EPS for Q4 2023
March 18, 2024
LTRN stock results show that Lantern Pharma beat analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028
March 20, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights
March 18, 2024
From
Lantern Pharma Inc.
Via
Business Wire
Earnings Scheduled For March 18, 2024
March 18, 2024
Companies Reporting Before The Bell • Niu Techs (NASDAQ:NIU) is expected to report earnings for its fourth quarter.
Via
Benzinga
Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284
March 15, 2024
From
Lantern Pharma Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.